Numab Therapeutics AG (Numab) and 3SBio Inc. ("3SBio", HKEX:1530) announced today that 3SBio's subsidiary Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. ("Sunshine Guojian") exercised its option
Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, today announced the appointment of Thomas Eldered as Chairman of the Board. Thomas Eldered succeeds Steve
KIYATEC clinical study data shows test accurately predicts brain cancer patient response eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
(0)
Forendo Pharma, a clinical-stage drug development company focusing on novel treatments in women s health, today announced the completion of Phase 1 studies in healthy volunteers for its lead development program in endometriosis, FOR-6219, and provided a development outlook. The successfully concluded Phase 1 program demonstrated that FOR-6219, a HSD17B1 enzyme-targeting small-molecule, was safe and well-tolerated and delivered additional results supporting Forendo s therapeutic concept. The company is now planning the Phase 2 program including endometriosis patients in the US. The now completed Phase 1 program delivered an initial body of tolerability, safety and pharmacokinetic data. For chronic endometriosis treatment, tolerability and a lack of systemic estrogen deficiency-related side effects are of the utmost importance as we see current therapies struggling to be widely adopted due to their side effect profiles. A local effect on the target tissue with our intracrinolog